1. Home
  2. CRNX vs TPH Comparison

CRNX vs TPH Comparison

Compare CRNX & TPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.66

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Tri Pointe Homes Inc.

TPH

Tri Pointe Homes Inc.

HOLD

Current Price

$46.95

Market Cap

4.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
TPH
Founded
2008
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.0B
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
CRNX
TPH
Price
$36.66
$46.95
Analyst Decision
Strong Buy
Hold
Analyst Count
8
5
Target Price
$76.75
$46.67
AVG Volume (30 Days)
1.3M
2.3M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.08
Revenue
$1,039,000.00
$3,260,447,000.00
Revenue This Year
$720.10
N/A
Revenue Next Year
$184.67
$10.20
P/E Ratio
N/A
$586.88
Revenue Growth
N/A
5.76
52 Week Low
$25.83
$28.72
52 Week High
$57.99
$46.99

Technical Indicators

Market Signals
Indicator
CRNX
TPH
Relative Strength Index (RSI) 45.46 66.98
Support Level $33.19 $46.24
Resistance Level $37.23 $46.99
Average True Range (ATR) 2.17 0.04
MACD -0.18 -0.05
Stochastic Oscillator 28.47 77.78

Price Performance

Historical Comparison
CRNX
TPH

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About TPH Tri Pointe Homes Inc.

Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. Its financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.

Share on Social Networks: